Presant C A, Scolaro M, Kennedy P, Blayney D W, Flanagan B, Lisak J, Presant J
Los Angeles Oncologic Institute, California 90057-0992.
Lancet. 1993 May 15;341(8855):1242-3. doi: 10.1016/0140-6736(93)91147-e.
Compared with conventional chemotherapy, use of liposomes loaded with therapeutic agents is less toxic and more effective in experimental tumours in vivo. We have assessed efficacy and toxicity of liposomal daunorubicin (40 mg/m2 every 2 weeks) in 25 patients with HIV-associated Kaposi's sarcoma of poor prognosis. In 24 evaluable patients, there were 2 complete remissions (8.3%) and 13 partial remissions (54.2%). 5 of 11 patients with doxorubicin-resistant Kaposi's sarcoma had partial remissions. Median duration of response was 12 weeks. Quality of life improved after treatment with a response rate of 71% for physical performance and 74% for emotion. Myelosuppression was the commonest adverse event. Vomiting, stomatitis, and alopecia were rare and mild. Liposomal daunorubicin is safe and effective in HIV-associated Kaposi's sarcoma and improves quality of life. The treatment is effective even in patients resistant to other chemotherapy.
与传统化疗相比，在体内实验性肿瘤中，使用负载治疗药物的脂质体毒性更低且效果更佳。我们评估了脂质体柔红霉素（每2周40mg/m²）对25例预后较差的HIV相关卡波西肉瘤患者的疗效和毒性。在24例可评估患者中，有2例完全缓解（8.3%），13例部分缓解（54.2%）。11例对阿霉素耐药的卡波西肉瘤患者中有5例部分缓解。缓解的中位持续时间为12周。治疗后生活质量得到改善，身体机能的缓解率为71%，情绪方面的缓解率为74%。骨髓抑制是最常见的不良事件。呕吐、口腔炎和脱发很少见且症状较轻。脂质体柔红霉素在HIV相关卡波西肉瘤中安全有效，可改善生活质量。即使对其他化疗耐药的患者，该治疗也有效。
